Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis

PURPOSE: Hangeshashinto (TJ-14, a Kampo medicine), which reduces the level of prostaglandin E2 and affects the cyclooxygenase activity, alleviates chemotherapy-induced oral mucositis (COM). We conducted a double-blind, placebo-controlled, randomized comparative trial to investigate whether TJ-14 pre...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Chemother Pharmacol
Glavni autori: Matsuda, Chu, Munemoto, Yoshinori, Mishima, Hideyuki, Nagata, Naoki, Oshiro, Mitsuru, Kataoka, Masato, Sakamoto, Junichi, Aoyama, Toru, Morita, Satoshi, Kono, Toru
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2015
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4485889/
https://ncbi.nlm.nih.gov/pubmed/25983022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2767-y
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items